Swing Therapeutics

Swing Therapeutics is a San Francisco-based digital therapeutics company founded in 2019 to develop software-based treatments and services for conditions where patients are underserved and digital interventions may be effective. Its focus is on autoimmune conditions and chronic overlapping pain conditions such as fibromyalgia, in which central pain sensitization is a significant factor. The company's lead product, Stanza, is a 12-week digital behavioral therapy for fibromyalgia symptoms delivered through a smartphone app and based on Acceptance and Commitment Therapy (ACT), a form of cognitive behavioral therapy. Treatment involves roughly 15 minutes of daily use, with lessons and interactive exercises intended to help patients apply ACT principles to their own circumstances.

Alongside the therapeutic itself, Swing operates Swing Care, a virtual specialty clinic launched in 2022 for fibromyalgia and chronic pain. Swing Care physicians and nurse practitioners can prescribe Stanza and provide additional services including medication management, mental health therapy, physical therapy, and coaching. Swing Therapeutics is not involved in the medical decisions of the practices delivering care; the practices operate under license from the corporate parent, which supplies administrative, management, and business support services, a structure used to comply with rules barring corporations from practicing medicine.

In July 2026 Swing Therapeutics and Swing Care were acquired by XRHealth, a medical virtual reality platform company based in Needham, Massachusetts, in what was reported as XRHealth's sixth acquisition in two years and its first move into smartphone-based treatments.

Founding story

Swing Therapeutics was founded in 2019 by Mike Rosenbluth, PhD, who holds BS and MS degrees in mechanical engineering from Stanford and a PhD from UC Berkeley, where he spent six years in Daniel Fletcher's biophysics lab studying cell mechanics. Before founding the company he worked about four years at McKinsey as an engagement manager on healthcare clients, two years at Versant Ventures, and five years at cancer diagnostics company Veracyte in pulmonology strategy and business development. He has described starting Swing to address the gap between Acceptance and Commitment Therapy's clinical evidence base and international fibromyalgia guideline recommendations on one hand, and patients' limited access to trained clinicians on the other, with a strategy of running a rigorous trial and publishing the data.

Business model

Swing develops a prescription digital therapeutic and pairs it with an affiliated telehealth clinic. Rather than waiting for broad health-plan coverage of Stanza as a standalone product, the company routes patients through Swing Care, whose clinicians prescribe Stanza and bill insurers for clinical services such as physician and nurse practitioner visits, medication management, therapy, physical therapy, and coaching even when Stanza itself is not covered. The clinical practices are independent and physician-owned, operating under license from the corporate parent, which provides administrative, management, and business support services.

Revenue derives from prescription digital therapy and associated virtual clinic services; billing for clinical services delivered by affiliated Swing Care practices is a route to reimbursement independent of coverage for Stanza itself. Highmark Health has issued a positive coverage decision for Stanza. Medicare began paying for FDA-cleared digital mental health treatments in 2025 and has considered but not extended coverage to Swing's treatment.

Traction

In the PROSPER-FM Phase 3 trial, 70.6% of Stanza users reported improvement on patient global impression of change over 12 weeks versus 22.2% in the control group, with no adverse events reported; results were published in The Lancet in July 2024. The earlier REACT-FM real-world study enrolled more than 100 people with fibromyalgia. At the time of acquisition the company said it was treating thousands of patients through its clinics, and Swing Care operated in several states including Illinois, Tennessee, and Texas.

Latest developments

On July 15, 2026, STAT reported that XRHealth had acquired Swing Therapeutics and Swing Care for undisclosed terms, the VR company's sixth acquisition in two years and its first in smartphone-based treatments. Founder and former CEO Mike Rosenbluth remained as a consultant; the company had other treatments in development that were not detailed. Prior to the acquisition, Swing had raised $30 million, including $11 million in the preceding year, and had secured Stanza coverage from Highmark Health.